Drug Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Drug Name Mosunetuzumab-axgb
Trade Name Lunsumio
Synonyms RG7828|BTCT4465A|RO7030816|BTCT-4465A
Drug Descriptions

Lunsumio (mosunetuzumab-axgb) is a bispecific antibody targeting CD20 and CD3, which may result in killing of CD20-positive tumor cells (PMID: 25972002, PMID: 29351372). Lunsumio (mosunetuzumab-axgb) is FDA approved for use in adult patients with relapsed or refractory follicular lymphoma who have received two or more lines of systemic therapy (FDA.gov).

DrugClasses CD20 Antibody 24 CD3 Antibody 99
CAS Registry Number 1905409-39-3
NCIT ID C129691

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Therapy Name Drugs Efficacy Evidence Clinical Trials
Atezolizumab + Mosunetuzumab-axgb Atezolizumab Mosunetuzumab-axgb 0 1
Atezolizumab + Mosunetuzumab-axgb + Tiragolumab + Tocilizumab Atezolizumab Mosunetuzumab-axgb Tiragolumab Tocilizumab 0 1
CC-99282 + Mosunetuzumab-axgb CC-99282 Mosunetuzumab-axgb 0 1
Cyclophosphamide + Doxorubicin + Etoposide + Mosunetuzumab-axgb + Prednisone + Vincristine Sulfate Cyclophosphamide Doxorubicin Etoposide Mosunetuzumab-axgb Prednisone Vincristine Sulfate 0 1
Cyclophosphamide + Doxorubicin + Mosunetuzumab-axgb + Polatuzumab vedotin-piiq + Prednisone Cyclophosphamide Doxorubicin Mosunetuzumab-axgb Polatuzumab vedotin-piiq Prednisone 0 2
Cyclophosphamide + Doxorubicin + Mosunetuzumab-axgb + Prednisone Cyclophosphamide Doxorubicin Mosunetuzumab-axgb Prednisone 0 1
Cyclophosphamide + Doxorubicin + Mosunetuzumab-axgb + Prednisone + Vincristine Sulfate Cyclophosphamide Doxorubicin Mosunetuzumab-axgb Prednisone Vincristine Sulfate 0 1
Iberdomide + Mosunetuzumab-axgb Iberdomide Mosunetuzumab-axgb 0 1
Lenalidomide + Mosunetuzumab-axgb Lenalidomide Mosunetuzumab-axgb 0 4
Lenalidomide + Mosunetuzumab-axgb + Polatuzumab vedotin-piiq Lenalidomide Mosunetuzumab-axgb Polatuzumab vedotin-piiq 0 1
Lenalidomide + Mosunetuzumab-axgb + Polatuzumab vedotin-piiq + Tafasitamab-cxix Lenalidomide Mosunetuzumab-axgb Polatuzumab vedotin-piiq Tafasitamab-cxix 0 1
Lenalidomide + Mosunetuzumab-axgb + Tocilizumab Lenalidomide Mosunetuzumab-axgb Tocilizumab 0 1
Loncastuximab tesirine-lpyl + Mosunetuzumab-axgb Loncastuximab tesirine-lpyl Mosunetuzumab-axgb 0 1
Mosunetuzumab-axgb Mosunetuzumab-axgb 0 11
Mosunetuzumab-axgb + Obinutuzumab + Polatuzumab vedotin-piiq Mosunetuzumab-axgb Obinutuzumab Polatuzumab vedotin-piiq 0 1
Mosunetuzumab-axgb + Polatuzumab vedotin-piiq Mosunetuzumab-axgb Polatuzumab vedotin-piiq 0 6
Mosunetuzumab-axgb + Polatuzumab vedotin-piiq + Tocilizumab Mosunetuzumab-axgb Polatuzumab vedotin-piiq Tocilizumab 0 1
Mosunetuzumab-axgb + Tazemetostat Mosunetuzumab-axgb Tazemetostat 0 2
Mosunetuzumab-axgb + Tiragolumab + Tocilizumab Mosunetuzumab-axgb Tiragolumab Tocilizumab 0 1
Mosunetuzumab-axgb + Tocilizumab Mosunetuzumab-axgb Tocilizumab 0 3
Mosunetuzumab-axgb + Zanubrutinib Mosunetuzumab-axgb Zanubrutinib 0 2


Additional content available in CKB BOOST